← SynDRA
AFATINIB
SynDRA canonical compound SYN0022649 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EGFR | ERBB2 | ERBB4 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ERBB2
- EGFR
- ERBB4
- ABL1
- MAPK14
- MAPK9
- MAPKAPK2
- MET
- MKNK1
- MKNK2
- MYLK
- PHKG1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- ERBB4 INHIBITOR
- Receptor protein-tyrosine kinase erbB-4 inhibitor
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- tovok
- afatinib dimaleate
- gilotrif
- BIBW2992
- afatinib maleate
- BIBW-2992
- TOMTOVOK
- TOVOK
- (E/Z)-AFATINIB
- (E/Z)-BIBW 2992
- AFATINIB (BIBW2992)
- Afatinib dimaleate
- AFATINIB FREE BASE
- BIBW2992 (AFATINIB)
- BIBW2992-MA2
- BIBW2992AFATINIBTOVOKS1011
- Gilotrif
- Giotrif
- NSC-750691
- Tomtovok
- Tovok
- Tovok (TN)
- Tovok, BIBW2992
- (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- EGFR inhibitor 2nd gens
- Afatinib (diMaleate)
- UNII-V1T5K7RZ0B
- BIBW 2992MA2
- Afatinib dimaleate [USAN]
- V1T5K7RZ0B
- CHEBI:76003
- Afatinib (BIBW2992) Dimaleate
- Afatinib maleate
- Afatinib dimaleate (USAN)
- Gilotrif (TN)
- Giotrif (TN)
- Afatinib maleate (JAN)
- (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate)
Reported adverse events
- Cheilitis
- Conjunctivitis
- Cystitis
- Dry skin
- Epistaxis
- Nausea
- Paronychia
- Pruritus
- Pyrexia
- Rash
- Stomatitis
- Toxic epidermal necrolysis
Look up AFATINIB in the interactive SynDRA portal →